More DTC Gene Test Firms Hit With FDA Untitled Letters
This article was originally published in The Gray Sheet
Executive Summary
FDA recently sent untitled letters to three direct-to-consumer genetic testing firms asking them to seek clearance for their making medical claims.
You may also be interested in...
Take Care In Promoting Lab-Developed Genetic Tests Or Risk US FDA, FTC Ire
Device-practice attorneys provide tips and precautions for laboratories advertising and promoting non-cleared or unapproved molecular-based diagnostics, and avoiding enforcement.
FDA, 23andMe Open Up Market Pathway For DTC Genetics
The Google-backed firm's carrier screening assay for a rare disease called Bloom syndrome is the first DTC genetic test to achieve sign off from FDA. More importantly, the marketing authority was awarded in a manner that could significantly streamline the path to market for future DTC carrier-screening assays.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”